Emergent BioSolutions Inc. (EBS) is a global life sciences firm specializing in the development, manufacture, and delivery of preparedness and response solutions that help address some of the most critical threats to public health safety. This multinational specialty biopharmaceutical company was founded in 1998 and has its headquarters in Gaithersburg, Maryland.
EBS is grounded in the philosophy that certain medical threats – particularly those that can lead to mass casualties in civilian populations – require specialized, tailored solutions. Their work therefore primarily caters to combating emerging infectious diseases, accidental and intentional misuse of harmful substances, and proponents of chemical, biological, radiological, nuclear, and explosives (CBRNE) threats.
In terms of product-range, EBS has a diversified portfolio that covers areas like bio-defense, therapeutics, vaccines, and devices. Some of the flagship products include BioThrax, the only FDA-approved Anthrax vaccine; Botulism anti-toxin Heptavalent; and various medical countermeasures for public health threats such as smallpox and chemical emergencies. Their role in the COVID-19 pandemic response by manufacturing vaccines highlights their expertise and commitment to public health safety.
Emergent BioSolutions's offerings are utilized by governments, healthcare providers, and also defense establishments internationally. They operate across North America and Europe, with expansive production facilities and development sites across the United States, the United Kingdom, Germany, and Canada.
EBS’s operations cover three key aspects: Contract Development and Manufacturing (CDMO) services, vaccination development, and delivery of public health solutions for governments across the globe. As a CDMO provider, EBS offers a full range of services, from early development, formulation, and analytical services, through to fill finish and packaging.
The team at Emergent BioSolutions Inc. includes passionate professionals who strive tirelessly to safeguard public health. Thanks to these dedicated efforts, EBS has established itself as a trusted partner to various governments and international agencies focused on bolstering health security and preparedness.
The company's comprehensive strategy, combined with its innovative research and adherence to stringent manufacturing standards, has made EBS not only a leading player in the biotech industry but also a cornerstone of public health defense worldwide. It continues to evolve, grow, and work on breakthroughs to protect and enhance life in the face of emerging threats.